/
Oncology
Advanced Solid Malignancies
25
Pipeline Programs↗
18
Active Trials↗
35
Companies Involved↗
Advanced Solid Malignancies is an emerging landscape with 25 programs across 35 companies. The most active players are AstraZeneca, Kumquat Biosciences Inc., Treadwell Therapeutics, Inc.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 18
Phase 210
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
18 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.
Analysis
Trial Status
94
clinical trials
Completed52 · 55%
Terminated17 · 18%
Recruiting11 · 12%
Active, not recruiting6 · 6%
Unknown status5 · 5%
Suspended2 · 2%
Other1 · 1%
Clinical Trials
Trial Activity
94 trials
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)